Ann L. Jackman
The Section of Medicine
Institute of Cancer Research
15 Cotswold Road
Belmont
UK
Name/email consistency: high
- A rationale for the clinical development of the thymidylate synthase inhibitor ZD9331 in ovarian and other solid tumours. Jackman, A.L., Melin, C.J., Kimbell, R., Brunton, L., Aherne, G.W., Theti, D.S., Walton, M. Biochim. Biophys. Acta (2002)
- Cellular pharmacology and in vivo activity of a new anticancer agent, ZD9331: a water-soluble, nonpolyglutamatable, quinazoline-based inhibitor of thymidylate synthase. Jackman, A.L., Kimbell, R., Aherne, G.W., Brunton, L., Jansen, G., Stephens, T.C., Smith, M.N., Wardleworth, J.M., Boyle, F.T. Clin. Cancer Res. (1997)